真菌性角膜炎后角膜瘢痕特征与视力的关联
这项前瞻性横断面辅助研究纳入71例MUTT I试验中接受过真菌性角膜炎治疗的患者,在入组约2年后进行视力、Scheimpflug成像和前段OCT检查。多变量线性回归显示,不规则散光和角膜瘢痕密度与最佳眼镜矫正视力(BSCVA)下降最相关,而角膜最薄点最能区分那他霉素和伏立康唑治疗组。
要点
- 不规则散光和角膜瘢痕密度是较轻度愈合真菌性角膜溃疡患眼BSCVA下降的重要危险因素。
- 角膜最薄点可能作为角膜特异性结局指标,用于评估角膜溃疡治疗。
- 那他霉素治疗眼较伏立康唑治疗眼角膜最薄点少变薄29.3 μm(95%CI 7.1-51.6 μm)。
核心结论
- 不规则散光和角膜瘢痕密度可能是相对轻度愈合真菌性角膜溃疡患眼BSCVA的重要危险因素。
- 角膜瘢痕最薄点可能作为角膜特异性结局指标用于评估角膜溃疡治疗。
研究设计与样本
- 前瞻性横断面辅助研究,纳入MUTT I试验中接受真菌性角膜炎治疗的71例患者,在印度一家转诊医院于入组约2年后进行检查。
- 检查包括最佳眼镜矫正视力(BSCVA)、最佳接触镜矫正视力、Scheimpflug成像和前段光学相干断层扫描。
- 数据收集时间为2012年12月3日至2012年12月19日,分析时间为2013年12月2日至2019年10月2日。
主要发现
- 71例患者中男性42例(59.1%),中位年龄48岁(范围39-60岁),检查时间中位(IQR)为入组后1.8(1.4-2.2)年。
- 平均(SD)logMAR BSCVA为0.17(0.19)(Snellen等效20/32)。
- 多变量线性回归中,BSCVA与不规则散光最相关(BSCVA与接触镜视力每差1行,BSCVA差1.0行;95%CI 0.6-1.4)。
- BSCVA与角膜瘢痕密度相关(中央角膜平均密度每增加10单位,视力差1.5行;95%CI 0.8-2.3)。
- 角膜最薄点最能区分MUTT I中那他霉素和伏立康唑治疗的溃疡,那他霉素治疗眼少变薄29.3 μm(95%CI 7.1-51.6 μm)。
关键数值与推荐
- BSCVA与不规则散光的关联:BSCVA与接触镜视力每差1行,BSCVA差1.0行(95%CI 0.6-1.4)。
- BSCVA与角膜瘢痕密度的关联:中央角膜平均密度每增加10单位,视力差1.5行(95%CI 0.8-2.3)。
- 那他霉素治疗眼较伏立康唑治疗眼角膜最薄点少变薄29.3 μm(95%CI 7.1-51.6 μm)。
临床怎么用
- 在真菌性角膜炎愈合后评估视力下降时,应关注不规则散光和角膜瘢痕密度。
- 角膜最薄点可作为临床试验中评估角膜溃疡治疗的角膜特异性结局指标。
局限性
- 本研究为MUTT I的子集分析,样本量71例,结论外推需谨慎。
- 研究人群为相对轻度、已愈合的真菌性角膜溃疡,结果可能不适用于更严重或其他类型角膜瘢痕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Corneal opacity is a leading cause of visual impairment worldwide; however, the specific features of corneal scars, which decrease visual acuity, have not been well characterized. OBJECTIVE: To investigate which features of a postfungal keratitis corneal scar contribute to decreased visual acuity after an episode of infectious keratitis and evaluate whether any corneal features may be used as outcomes for clinical trials. DESIGN, SETTING, AND PARTICIPANTS: In this ancillary, prospective cross-sectional study, a subset of study participants treated for fungal keratitis (n = 71) as part of the Mycotic Ulcer Treatment Trial I (MUTT I) underwent best spectacle-corrected visual acuity (BSCVA) and best contact lens-corrected visual acuity examination, Scheimpflug imaging, and anterior segment optical coherence tomography at a referral hospital in India approximately 2 years after enrollment. Data were collected from December 3, 2012, to December 19, 2012, and analyses were performed from December 2, 2013, to October 2, 2019. MAIN OUTCOMES AND MEASURES: Linear regression models were used to evaluate the importance of various corneal features for BSCVA and to assess whether these features could be used to differentiate the 2 treatment arms of the MUTT I trial. RESULTS: Seventy-one patients (42 men [59.1%]; median age, 48 [range, 39-60] years) were examined at a median (IQR) time of 1.8 (1.4-2.2) years after enrollment. The mean (SD) logMAR BSCVA was 0.17 (0.19) (Snellen equivalent, 20/32). In multivariable linear regression models, BSCVA was most associated with irregular astigmatism (1.0 line of worse BSCVA per 1-line difference between BSCVA and contact lens visual acuity; 95% CI, 0.6-1.4) and corneal scar density (1.5 lines of worse vision per 10-unit increase in the mean central corneal density; 95% CI, 0.8-2.3). The thinnest point of the cornea was the metric that best discriminated between the natamycin- and voriconazole-treated ulcers in MUTT I, with 29.3 μm (95% CI, 7.1-51.6 μm) less thinning in natamycin-treated eyes. CONCLUSIONS AND RELEVANCE: Both irregular astigmatism and corneal scar density may be important risk factors for BSCVA in a population with relatively mild, healed fungal corneal ulcers. The thinnest point of the corneal scar may be a cornea-specific outcome that could be used to evaluate treatments for corneal ulcers.
引用
- Menda SA, Das M, Panigrahi A, et al. Association of Postfungal Keratitis Corneal Scar Features With Visual Acuity. JAMA Ophthalmol. 2020. PMID: 31804657. doi:10.1001/jamaophthalmol.2019.4852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。